India offers cutting-edge, affordable treatment for Myelodysplastic Syndromes (MDS)—a group of bone marrow disorders causing abnormal blood cell production. Treatment options range from supportive care to stem cell transplant, costing between $6,000 – $25,000 depending on risk category and treatment type. The same treatment costs $60,000 – $150,000 in the USA and $18,000 – $35,000 in Thailand, making India a globally preferred destination for MDS care.
Myelodysplastic Syndromes (MDS) are a group of disorders in which the bone marrow fails to produce enough healthy blood cells. These conditions affect the production of red blood cells, white blood cells, and platelets, often leading to fatigue, infections, and bleeding. MDS can remain stable for years in some patients, while others may progress to acute myeloid leukemia (AML), a more aggressive form of cancer.
Causes:
Symptoms:
Risk Factors:
MDS is classified by the World Health Organization (WHO) and the French-American-British (FAB) system based on cell types and bone marrow appearance:
Common WHO Subtypes:
FAB Classifications Include:
Dr. Ankur Bahl is a leading hematologist-oncologist in India known for his success in treating complex blood disorders including MDS. He is:
Treatment depends on MDS subtype, risk level, age, and overall health.
A. Supportive Therapy:
B. Disease-Modifying Agents:
C. Immunosuppressive Therapy:
D. Allogeneic Stem Cell Transplant (ASCT):
E. Clinical Trials and Targeted Therapy:
|
Treatment Component |
Estimated Cost (USD) |
|
Diagnostic Workup (Lab Tests, Biopsy) |
$800 – $1,200 |
|
Cytogenetic and Molecular Testing |
$600 – $1,000 |
|
Drug Therapy (per cycle of Azacitidine) |
$1,000 – $2,000 |
|
Blood Transfusions (per unit) |
$100 – $200 |
|
Immunosuppressive Therapy |
$2,000 – $4,000 |
|
Allogeneic Stem Cell Transplant (ASCT) |
$15,000 – $25,000 |
|
Hospital Stay & Post-Care Monitoring |
$1,200 – $2,500 |
|
Total Estimated Range |
$6,000 – $25,000 |
|
Country |
Total Cost Estimate (USD) |
|
India |
$6,000 – $25,000 |
|
USA |
$60,000 – $150,000 |
|
Thailand |
$18,000 – $35,000 |
|
UK |
$45,000 – $100,000 |
India offers the most cost-effective option with access to the same medications, infrastructure, and expertise.
Conclusion India is a global leader in affordable and effective Myelodysplastic Syndromes (MDS) treatment, offering everything from diagnostics to curative stem cell transplant under expert supervision. With specialists like Dr. Ankur Bahl, modern technology, and international support services, India delivers world-class care at one-third the global cost—making it an optimal destination for patients seeking hope and healing
MDS is considered a bone marrow failure disorder that can behave like cancer. High-risk MDS can evolve into acute myeloid leukemia (AML).
Supportive and drug therapies manage MDS effectively. Allogeneic stem cell transplant offers the only potential cure.
Yes. Once diagnostic reports are evaluated, treatment can usually begin within 5–7 days of arrival in India.
Yes. India has several internationally certified transplant units with HEPA filtration and isolation rooms.
Medical clearance is advised. Some patients may require blood transfusions prior to travel.
Yes. You can email your reports to Indian hospitals or directly to Dr. Ankur Bahl’s team for a treatment plan.
Yes. Drugs like Azacitidine, Decitabine, and supportive medications are available in India, often at a lower cost.
Options include haploidentical (half-matched) transplants, cord blood, or continuing with drug therapy.
Typically, 6–8 weeks including pre-transplant workup, transplant, and early recovery.
Yes. Indian hospitals provide virtual follow-up and coordination with local doctors abroad.